We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

170 hedge funds and large institutions have $398M invested in Allogene Therapeutics in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 22

10% more funds holding

Funds holding: 154 → 170 (+16)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less capital invested

Capital invested by funds: $413M → $398M (-$15.5M)

4% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 52

4.09% less ownership

Funds ownership: 77.73% → 73.64% (-4.1%)

79% less call options, than puts

Call options by funds: $96K | Put options by funds: $451K

Holders
170
Holders Change
+16
Holders Change %
+10.39%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
39
Increased
50
Reduced
52
Closed
22
Calls
$96K
Puts
$451K
Net Calls
-$355K
Net Calls Change
-$81K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.54M
2
Goldman Sachs
Goldman Sachs
New York
+$5.47M
3
Millennium Management
Millennium Management
New York
+$5.09M
4
BlackRock
BlackRock
New York
+$3.14M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$16.4M
2
EC
EcoR1 Capital
California
-$14.2M
3
WP
Woodline Partners
California
-$7.76M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$4.42M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$81M +$277K +97,568 +0.4%
TGA
2
TPG GP A
Texas
$60.1M – – –
BlackRock
3
BlackRock
New York
$32.1M +$3.14M +1,107,824 +12%
Vanguard Group
4
Vanguard Group
Pennsylvania
$29M -$4.42M -1,556,979 -15%
JP Morgan Chase
5
JP Morgan Chase
New York
$22.2M -$11.7K -4,121 -0.1%
Primecap Management
6
Primecap Management
California
$17M -$7.09K -2,500 -0%
Citadel Advisors
7
Citadel Advisors
Florida
$13M -$177K -62,404 -2%
Goldman Sachs
8
Goldman Sachs
New York
$10.7M +$5.47M +1,929,258 +137%
Morgan Stanley
9
Morgan Stanley
New York
$10.7M +$5.54M +1,953,934 +141%
WP
10
Woodline Partners
California
$8.27M -$7.76M -2,736,415 -51%
State Street
11
State Street
Massachusetts
$7.79M -$16.4M -5,775,317 -70%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$7.61M -$102K -35,875 -1%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$7.5M +$748K +263,842 +13%
Two Sigma Investments
14
Two Sigma Investments
New York
$7.43M +$2.88M +1,014,320 +78%
WCM
15
Wildcat Capital Management
New York
$6.17M – – –
Millennium Management
16
Millennium Management
New York
$6.16M +$5.09M +1,794,616 +1,443%
VVA
17
Vida Ventures Advisors
Massachusetts
$5.77M – – –
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$4.93M -$860K -303,111 -16%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$4.1M +$852K +300,500 +31%
Northern Trust
20
Northern Trust
Illinois
$3.26M +$436K +153,818 +18%
CANY
21
Caxton Associates (New York)
New York
$2.49M +$837K +294,989 +61%
Nordea Investment Management
22
Nordea Investment Management
Sweden
$2.38M -$67.5K -23,805 -3%
Charles Schwab
23
Charles Schwab
California
$2.35M -$138K -48,493 -6%
Swedbank
24
Swedbank
Sweden
$2.25M -$612K -215,835 -24%
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$2.18M +$1.93M +679,468 New
1
2 3 4 5

ALLO Hedge Fund Activity: Q4 2023 in Review

170 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2023, worth a combined $398M — down 3.8% from $413M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ALLO positions and 22 closed out — a net gain of 17 holders — while 50 added to existing stakes and 52 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.54M. The largest seller was State Street, cutting an estimated $16.4M.

  • 170 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2023, up from 154 in Q3 2023.
  • Funds reported $398M of Allogene Therapeutics stock for Q4 2023, down 3.8% quarter-over-quarter.
  • 39 funds opened new Allogene Therapeutics positions in Q4 2023 and 22 closed out, a net change of +17 holders.
  • The largest Allogene Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $5.54M added.
  • The largest Allogene Therapeutics seller in Q4 2023 was State Street, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2023.